NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,457.29 +250.16 (+1.37%) CRUDE OIL
79.25 +0.30 (+0.38%) GOLD FUTURES
2,316.80 +7.20 (+0.31%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,468.94 +1,819.47 (+3.99%)
Taro Pharmaceutical Industries Ltd. (TARO)
After hours:
| Previous close | 42.39 |
| Open | 42.48 |
| Bid | 0.00 x 2900 |
| Ask | 0.00 x 800 |
| Day's range | 42.29 - 42.56 |
| 52-week range | 26.58 - 45.76 |
| Volume | |
| Avg. volume | 44,529 |
| Market cap | 1.598B |
| Beta (5Y monthly) | 0.61 |
| PE ratio (TTM) | 34.84 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 10 Dec 2018 |
| 1y target est | N/A |
- Reuters
India's Sun Pharma to buy remaining stake in Israeli unit Taro for about $348 million
The Indian drugmaker, which currently owns about 78.5% stake in Taro, had offered to buy its remaining stake for $38 per share in May. Upon completion of the merger, which is expected to close in the first half of the year, Taro would become a privately held company and will be delisted from the New York Stock Exchange, the companies said. The U.S. government had in November dismissed charges against a former Taro executive who was accused of conspiring to fix generic drug prices between 2013 and 2015.
- Zacks
Amicus (FOLD) Banks on Galafold, Overdependence a Concern
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
- Zacks
Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
